Extracellular matrix stiffness influences biological functions of some tumors. However, it remains unclear how cancer subtypes with different oncogenic mutations respond to matrix stiffness. In addition, the relevance of matrix stiffness to in vivo tumor growth kinetics and drug efficacy remains elusive. Here, we designed 3D hydrogels with physical parameters relevant to hematopoietic tissues and adapted them to a quantitative high-throughput screening format to facilitate mechanistic investigations into the role of matrix stiffness on myeloid leukemias. Matrix stiffness regulates proliferation of some acute myeloid leukemia types, including MLL-AF9 + MOLM-14 cells, in a biphasic manner by autocrine regulation, whereas it decreases that of chronic myeloid leukemia BCR-ABL + K-562 cells.
Extracellular matrix stiffness influences biological functions of some tumors. However, it remains unclear how cancer subtypes with different oncogenic mutations respond to matrix stiffness. In addition, the relevance of matrix stiffness to in vivo tumor growth kinetics and drug efficacy remains elusive. Here, we designed 3D hydrogels with physical parameters relevant to hematopoietic tissues and adapted them to a quantitative high-throughput screening format to facilitate mechanistic investigations into the role of matrix stiffness on myeloid leukemias. Matrix stiffness regulates proliferation of some acute myeloid leukemia types, including MLL-AF9 + MOLM-14 cells, in a biphasic manner by autocrine regulation, whereas it decreases that of chronic myeloid leukemia BCR-ABL + K-562 cells.
Although Arg-Gly-Asp (RGD) integrin ligand and matrix softening confer resistance to a number of drugs, cells become sensitive to drugs against protein kinase B (PKB or AKT) and rapidly accelerated fibrosarcoma (RAF) proteins regardless of matrix stiffness when MLL-AF9 and BCR-ABL are overexpressed in K-562 and MOLM-14 cells, respectively. By adapting the same hydrogels to a xenograft model of extramedullary leukemias, we confirm the pathological relevance of matrix stiffness in growth kinetics and drug sensitivity against standard chemotherapy in vivo. The results thus demonstrate the importance of incorporating 3D mechanical cues into screening for anticancer drugs.
matrix stiffness | systems pharmacology | biomaterials | drug screening | cancer M yeloid leukemias originate from the hematopoietic stem cell compartment in bone marrow (BM) after oncogenic mutations. For instance, a translocation between parts of the human chromosome 22 and 9 results in the BCR-ABL fusion gene that causes chronic myeloid leukemia (CML) (1) . Some translocations involving the mixed lineage leukemia (MLL) gene in the human chromosome 11, band q23, such as the MLL-AF9 fusion gene, are involved in acute myeloid leukemia (AML) (2) . In addition to mutations, hematopoietic microenvironments can contribute to pathogenesis and progression of myeloid leukemias (3) . Both oncoproteins and cell-extrinsic factors are known to perturb various signaling pathways that regulate key biological processes in cancer. For instance, AKT/PKB (protein kinase B) is a major signaling node downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase and has been targeted by a number of drugs to inhibit cancer cell survival and growth (4) . Recently, physical cues from microenvironments have emerged as important regulators of tumor biology, such as extracellular matrix stiffness and collagen architecture (5, 6) . Matrix stiffness also regulates normal hematopoiesis (7, 8) . However, the relevance of physical cues to blood cancer remains largely unclear. Importantly, how different cancer subtypes with distinct oncogenic mutations respond to matrix stiffness also remains to be investigated.
Recent studies highlight the utility of adapting 3D culture into a high-throughput screening assay to better predict in vivo efficacy of anticancer drugs compared with conventional 2D culture (9, 10). However, physical properties of microenvironments were not considered in this assay format for cancer drug discovery. Effects of matrix stiffness on chemosensitivity were previously evaluated with breast cancer (11) and hepatocellular carcinoma cells (12) on 2D hydrogel systems, and with melanoma cells in 3D hydrogel systems (13) . However, it is not clear whether these in vitro results inform in vivo drug efficacy. In general, it is largely unknown whether 3D matrix stiffness systematically influences responses of cancer cells to different drugs and potentially contributes to a failure to eradicate residual disease.
Here, we introduce a niche-based quantitative biophysical screen to evaluate the impact of 3D matrix stiffness on proliferation and drug sensitivity of different human myeloid leukemia subtypes. First, we altered mechanical properties of hydrogels so that they can closely mimic a range of physiological tissue stiffness relevant to the hematopoietic system. Leukemia cells were then encapsulated in the hydrogels and dispensed into a 96-multiwell assay format. Mechanistic studies using this system revealed distinct growth patterns and pharmacodynamics profiles of drugs against different leukemia subtypes as a function of matrix mechanics, highlighting relationships between genetic mutations and physical environments. Finally, the same hydrogel system was used in an in vivo xenograft model to validate the in vitro findings that matrix softening leads to resistance against standard chemotherapy.
Results

Matrix Mechanics Differentially Regulates Proliferation of Myeloid
Leukemia Subtypes. When blood cells differentiate in the BM and traffic into the circulation, they transit from a solid-phase Significance Most chemotherapy drugs treat, but do not cure, cancer patients due to resistance. New high-throughput screening assays are emerging to better predict drug efficacy by recapitulating tumor microenvironments with three-dimensional hydrogels. Our platform exploits the mechanical tunability of alginate hydrogels to introduce biophysical cues into screening assays. The utility of this approach is demonstrated with the findings of unique modes of growth modulation by matrix stiffness and mechanosensitivity of drug actions in different myeloid leukemia subtypes. The same hydrogels were then adapted to confirm in vivo that matrix softening accelerates cancer growth kinetics and causes resistance to standard chemotherapy. We anticipate that this integrative workflow will be broadly useful to discover drugs that target cancer cells in different physical environments. microenvironment to a viscous phase (14) (Fig. 1A) . A similar transition also occurs outside the BM ("extramedullary" sites) when peripheral blood cells undergo intravasation from tissues. To generalize this mechanical transition, alginate was used to form hydrogels, because ionic cross-linking controls hydrogel stiffness independent of pore size, ensuring constant diffusion of molecules up to hundreds of kilodaltons (15) . Importantly, adhesion ligands can be conjugated at different densities and controlled independent of stiffness. The hydrogel was conjugated with different densities of the Arg-Gly-Asp (RGD) peptide, which binds preferentially to α 5 β 1 and α v β 3 /β 5 integrins, mixed with leukemia cells and ionically cross-linked to provide varied stiffness, ranging from soft solid (Young's modulus, E = 0.075∼3 kPa) to viscous uncross-linked (E = "0" kPa) matrix in 96-well plates (Fig. S1A) . Because the BM is generally viscoelastic (16) , ionic cross-linking is more appropriate than covalent cross-linking because of the stress relaxation behavior (17) . The average E for in situ BM is ∼0.3 kPa (8). The minimum E achieved with alginate hydrogels is ∼0.075 Pa (5), whereas ∼3 kPa is close to the E of a number of soft tissues (18) or stiffer parts of the marrow. Without crosslinking, the alginate fluid in this study recapitulates the known viscosity value of blood under low shear (∼40 cP) (16) . This platform thus allows individualized ex vivo testing of disease progression and drug sensitivity in a high-throughput format, which could inform personalized therapies to target cancer cells in different biophysical environments (Fig. 1A) .
We characterized how different myeloid leukemia subtypes with distinct genetic mutations respond to varied stiffness and ligand density. A representative human cell line from each myeloid leukemia subtype was used: AML with MLL-AF9 (MOLM-14), AML without MLL-AF9 (U-937), and CML with BCR-ABL (K-562). These cells are known to express α 5 β 1 , which binds to the RGD sequence in fibronectin (19) . In general, leukemia cells grow as amorphous aggregates in the viscous matrix and as single large spheres in the solid matrices (Fig. 1A) . In all cases, there is a net increase in cell number of at least ∼10-fold at day-7 culture. Within this time frame, AML cells show biphasic proliferation responses across matrix mechanics whereas CML cells show a stiffness-dependent decrease in cell number (Fig. 1B) . Increasing RGD density significantly increases the maximal cell number at 0.3 kPa for MOLM-14, whereas it shifts the curve to the right for U-937. In contrast, ligand density does not significantly affect proliferation of K-562. Therefore, this screen is potentially useful to resolve each myeloid leukemia subtype based on distinct proliferation profiles as a function of matrix mechanics.
Autocrine Feedback Is Sufficient to Explain the Biphasic AML Growth with Matrix Stiffening. To explore mechanisms behind the biphasic response of AML cells, we asked whether matrix stiffening represents a component in biological circuits that can carry out two simultaneously opposing effects on cell growth and death. Because leukemia cells secrete a number of cytokines that can serve as autocrine signals (20), we hypothesized that matrix stiffening increases AML proliferation, but also leads to secretion of soluble factors that affect cell death. We first addressed this hypothesis by developing a computational model with a set of ordinary differential equations. In this model, the cell proliferation rate and the factor secretion rate depend on matrix stiffness in a sigmoidal function (Michaelis-Menten kinetics), whereas the cell death rate depends on the concentration of soluble factors in a linear function (Fig. 2 A, i) . This model is sufficient to show a biphasic growth pattern with matrix stiffening (SI Methods) and simulate the experimental results with AML cells. Two parameters are important: (i) potency of factor secretion in response to matrix stiffening [E at half maximal δ(E): "δE 50 " in pascals] and (ii) potency of cell proliferation in response to matrix stiffening [E at half maximal β(E): "βE 50 " in pascals]. Higher values of these two parameters mean lower sensitivities. Interestingly, increasing δE 50 alone increases the amplitude of the biphasic curve ( Fig. 2 A, ii) , whereas increasing both δE 50 and βE 50 shifts the curve to the right (Fig. 2 A, iii) . The curves generated from an analytically derived equation also recapitulate this trend (SI Methods). These two results simulate the growth profiles of MOLM-14 and that of U-937, respectively. The results also predict that increasing the RGD ligand density should decrease the sensitivity of factor secretion upon matrix stiffening in MOLM-14 cells, whereas it should decrease both the sensitivity of factor secretion and that of cell proliferation upon matrix stiffening in U-937 cells. Consistent with this model, the conditioned media derived from cells in the matrix at 3 kPa suppress proliferation of AML cells cultured on plastic (Fig. 2B) , as contrasted to conditioned media from cells cultured in softer gels or on plastic. The cell number at the time of collecting the conditioned media (week 1) remains the same across different conditions (Fig. 1B) . The results can also be potentially explained by decreased secretion of proliferation promoting factors. Some cytokines are secreted in an autocrine manner to simultaneously regulate both cell growth and death, and this paradoxical regulation can be required to maintain stable steady-state cell concentrations (21) . However, mathematically, no biphasic relationship between cell number and matrix stiffness exists in a model when secreted factors directly regulate both cell growth and death rates (SI Methods). Although more complex scenarios are possible, the goal here is to identify a parsimonious model to explain the experimental data using a minimal number of variables and functions. The results thus indicate that an autocrine feedback mechanism could regulate the biphasic AML growth induced by matrix stiffening. AKT becomes more phosphorylated with matrix stiffening (5) and is required for autocrine secretion in some solid tumor cells (22) . showing recapitulation of mechanical properties relevant to the hematopoietic system by ionic cross-linking of alginate hydrogels, followed by adaptation of the 3D hydrogels into quantitative screening and animal validation. (B) Different myeloid leukemia subtypes show distinct proliferative responses against matrix mechanics and ligand density. Ligand density is controlled by "degree of substitution" (DS), which indicates the number of RGD peptides conjugated per alginate molecule (0∼20). The whole cell population was used for viability analysis. The data were fit to biphasic dose-response curves for AML cells and standard dose-response inhibition curves for CML cells. *P < 0.05 from one-way ANOVA with Tukey's honestly significant difference (HSD) test.
We thus explored whether inhibition of AKT reverses the biphasic AML growth with matrix stiffening. MK-2206 (MK) is an inhibitor against AKT that is in a clinical trial for treatment of solid tumors (23) . Interestingly, MK equalizes the number of MOLM-14 across different stiffness at a dose close to IC 50 (100 nM) ( Fig. 2 C, i) . The effect is moderate but significant for U-937 at a higher dose (1,000 nM) ( Fig. 2 C, ii) . Consistent with these results, the IC 50 for suppressing cell proliferation by MK is generally similar regardless of culture environments for AML cells (Fig. S1B ). Regardless of the basal level of phosphorylated AKT (pAKT) in different AML cells across different matrix stiffness (Fig. S1C ), MK decreases pAKT in both AML cells with IC 50 ∼50 nM at 300 Pa (Fig. S1D) . The results thus suggest that AKT inhibition can reverse the matrix stiffness-induced biphasic AML growth because the sensitivity of the AML cells to MK is independent of matrix stiffness.
Matrix Stiffness Modulates Chemosensitivity: Systematic Characterization by Biophysical Screening. In contrast to AML MOLM-14 and U-937 cells, CML K-562 cells become resistant to MK in 3D matrices, whereas they respond to MK on plastic ( Fig. 2 C, iii) . Indeed, K-562 cells show 10∼20-fold higher IC 50 values of MK in 3D matrices than on plastic (Fig. S1B) . Therefore, the same target can exhibit differential chemosensitivity with matrix mechanics in a leukemia celltype-dependent manner. This motivated broader investigations into how different molecular targets show chemosensitivity as a function of matrix mechanics. To achieve this goal, we first performed doseresponse characterization of select drugs against K-562 cells in our screen system. To facilitate this investigation in a high-throughput format, K-562 cells were virally transduced with mCherry and firefly luciferase (Fig. S2A ). The clone 3 shows similar proliferation kinetics as the whole cell population (Fig. S2B ) and was used in subsequent studies. Fluorescence signals are linearly proportional to the number of viable cells in hydrogels (Fig. S2C) . The tested drugs are either approved by the Food and Drug Administration for treatment of cancers or used to perturb targets involved in mechanotransduction (Table S1 ). K-562 cells do not respond to two of the tested drugs, including fasudil (Rhokinase inhibitor) and ruxolitinib (JAK inhibitor). Interestingly, hierarchical clustering analysis of IC 50 values across different stiffness classifies the remainder of the tested drugs into three categories for K-562 cells (Fig. 3A) . First, cells become resistant to ∼28% of the tested drugs, including doxorubicin and MK, in the RGD ligand-conjugated hydrogel, regardless of matrix stiffness ("class I"). Second, cells are sensitive to ∼44% of the drugs, including imatinib, a clinically used inhibitor against CML, and cytosine arabinoside (Ara-C), in a matrix stiffness-dependent manner ("class II"). Third, cells respond to drugs that target the RAF/MAPK pathway (Sorafenib, PD-98059) and the JNK pathway (SP-600125) with similar IC 50 values across different matrix stiffness ("class III"). Indeed, IC 50 values are significantly decreased upon matrix stiffening for class II but not for class I and III drugs (Fig. S3A) . The negative correlation observed with class II drugs is still significant when drugs from all of the classes are combined (Fig. S3B) . The same trend is also observed with the area under curve (AUC) parameter considering all of the drug classes ( Fig. S3C ), as expected because IC 50 and AUC generally correlate with each other (24) . No significant trend was observed with the Hill slope (m) parameter (Fig. S3D ), suggesting that potency is a unique parameter that can be used to classify drugs as a function of matrix mechanics.
Dose-response of the same select drugs was also characterized against MOLM-14 cells for systematic comparison with K-562 cells. Hierarchical clustering again classifies these drugs into class I-III for MOLM-14 cells (Fig. 3B ). Some of the tested drugs belong to different classes with MOLM-14 cells, compared with K-562 cells. Interestingly, MK is a class III drug, whereas drugs against RAF/MAPK and JNK belong to class II with MOLM-14 cells (Fig. 3B ). The resistance of both K-562 and MOLM-14 cells against their class I and class II drugs was found to depend on the presence of RGD, because the absence of RGD in the hydrogel abolishes differences in IC 50 between the hydrogel and plastic or across matrix stiffness ( 1000, 100 300, 100 Table S1 ) in 3D hydrogels conjugated with the RGD peptide (DS = 5) were normalized by respective IC 50 values from plastic, and then log-transformed before hierarchical clustering analysis. Drugs are classified into three classes: class I (ligand sensitive), class II (ligand and matrix stiffness sensitive), and class III (mechanics independent). The data were derived from n ≥ 15 experiments for A and n ≥ 4 experiments for B. Bold, underlined drugs belong to different classes in K-562 and MOLM-14 cells.
pathway, whereas the opposite trend is observed with MLL-AF9 + MOLM-14 cells. We thus sought to better understand how gene products that define leukemia subtypes affect the regulation of chemosensitivity by matrix mechanics. A physical interaction network was computationally constructed from a list of experimentally verified protein-protein interactions from curated databases (SI Methods). The network shows that BCR and ABL1 proteins interact more directly with the RAF/MAPK pathway components but less with the AKT pathway components (Fig. S4B) . The opposite trend is observed with AF9 (MLLT3) protein. Based on the results in Fig. 3 , the network analysis suggests a possibility that BCR-ABL and MLL-AF9 confer sensitivity to RAF/MAPK and AKT inhibitors, respectively, regardless of matrix stiffness. To test this idea, retroviral transduction was used to introduce BCR-ABL and MLL-AF9 to MOLM-14 and K-562 cells, respectively, followed by drug studies. Cells transduced with empty vectors were used as control (Fig. S5A) . The protein expression level of MLL-AF9 introduced in K-562 cells is comparable to the endogenous level in MOLM-14 cells, whereas the expression level of BCR-ABL in MOLM-14 cells is comparable to the endogenous level in K-562 cells (Fig. S5B) . MLL-AF9 significantly increases the sensitivity of K-562 cells against MK across different matrix stiffness (Fig. 4 A, i) , switching the class from I to III (Fig. 3A) , whereas it does not cause resistance against sorafenib (Fig. 4 A, ii) . However, BCR-ABL increases the sensitivity of MOLM-14 cells against sorafenib, switching the class from II to III (Fig. 3B) , whereas it does not cause resistance against MK (Fig. 4B) . Therefore, some oncogenes can decouple the dependence of chemosensitivity against specific pathways on matrix ligand or stiffness. −/− (NSG) mice (Fig. 5 A, i) . No difference in total viable cell number across different matrix stiffness was observed after cell encapsulation (Fig. S6A) . Because tumor was not visible by eye for the first 3 wk, bioluminescence live imaging for firefly luciferase in K-562 cells was used to track in vivo growth during this time frame (Fig.  5 A, i) . The in vivo growth follows the first-order kinetics at the natural log scale as described by the classical Gompertz model of tumor growth (26) (Fig. 5 A, ii and SI Methods). Specifically, matrix stiffening decreases both the initial growth rate and the deceleration rate by ∼1.5-fold (Fig. 5 A, iii and iv), and hence maintains a constant maximal tumor signal (i.e., plateau = growth/ deceleration). The results are consistent with the in vitro growth kinetics measured for 2 wk (Fig. S6B) . The in vivo cell number in soft matrix is up to ∼100-fold higher than that in stiff matrix at 2 wk (SI Methods), and the difference gradually diminishes afterward (Fig. S6C) . Therefore, initial matrix stiffening leads to both delayed and sustained cancer growth in vivo.
We then tested whether soft matrix confers resistance to standard chemotherapy in vivo as observed the in vitro drug screen studies. After 1-wk implantation, a myelosuppresive dose of Ara-C [62.5mg/kg (27) ] was intraperitoneally administered daily into each mouse for 3 wk (Fig. 5 B, i) . Interestingly, fitting the bioluminescence data for the first 3 wk shows that Ara-C suppresses the cell growth in the stiff matrix predominantly by increasing deceleration rate (∼2.5-fold) rather than decreasing initial growth rate (Fig. 5 B, ii) . In fact, initial growth rate in stiff matrix is increased slightly by ∼1.4-fold after Ara-C (Fig. S6 D, i) . It is thus estimated that Ara-C decreases the plateau of the tumor signal in the stiff matrix by ∼1.6-fold (Fig. S6 D, i) . In contrast, cells are resistant to Ara-C in the soft matrix (Fig. S6 D, ii) . To confirm these results, we investigated whether the treatment affects tumor growth at later time points after the withdrawal for 2 wk. An overall tumor volume rather than bioluminescence was measured at week 6 (SI Methods), because bioluminescence signals become saturated at week 4 (Fig. S6E) . The tumor volume remains higher in soft than in stiff matrix at week 6, with the difference less than an order of magnitude (Fig. 5 B, iii) . Consistent with the prediction from the earlier time points (Fig. S6 D, i) , Ara-C decreases the volume of tumors originating from stiff but not soft matrix (Fig. 5  B, iii), in a dose-dependent manner (Fig. S6F) .
Considering that the diameter of leukemia cells is ∼10 μm, the initial 1 million implanted K-562 cells per 20 μL gel disk occupies ∼2.5% of the total gel volume. This means that after 1 wk, when the tumor luminescence is increased by >40 fold (Fig. 5A) , the cell number reaches the limit of the initial scaffold volume. Indeed, histological analyses after 2 wk from the implantation show that both blood and stromal-like cells are present with gel fragments, suggesting both donor cell overgrowth and host cell infiltration (Fig. S7A ). This could be explained by stress relaxation of hydrogels followed by the loss of structural integrity, which is typical of ionically cross-linked hydrogels as cells proliferate (28) . Histological observations suggest a qualitative trend where fewer stromal-like cells may be present with Ara-C compared with vehicle control, but more dead hematopoietic cells are visible in stiff matrices compared with soft (Fig. S7B) . This is likely due to increased apoptosis, as indicated by increased cleaved caspase-3 staining (Fig. S8A) . To characterize mechanobiological features further, we performed immunofluorescence studies on implanted K-562 cells. Whereas nonhuman stromal-like cells generally express higher yes-associated protein (YAP), a mechanosensitive transcription factor (29) , than human K-562 cells, YAP + human cells are more visible in the stiff matrix compared with the soft matrix (Fig. S8B) . No difference was observed in F-actin distribution. Ara-C does not seem to alter these trends. Together, the results show that initial matrix softening increases resistance against standard chemotherapy.
Discussion
A variety of molecular signals emanating from stromal cells in the BM microenvironment are known to play important roles in modulating tumor survival and drug sensitivity. The use of tumorstroma coculture systems to identify new small-molecule inhibitors against tumor cells highlights the importance of recapitulating different components of the microenvironment to discover next-generation cancer therapies. Prior efforts have primarily focused on incorporating molecular and cellular components into in vitro drug screens on culture plastic. We demonstrate that engineering biophysical factors of the microenvironment, especially 3D matrix stiffness, into a quantitative, high-throughput screen format (Fig.  1A ) reveals systematic variations in proliferation and drug responses of myeloid leukemias. Matrix stiffening initially enhances the proliferation of MOLM-14 and U-937 cells but suppresses that of K-562 cells (Fig. 1B) . This result mirrors the previous observation that TGF-β1 secreted from parathyroid hormone receptor-stimulated osteoblasts in vivo enhances MLL-AF9 + AML proliferation but attenuates BCR-ABL + CML (3). Because TGF-β1 also regulates leukemia cells in an autocrine manner (30) , it is possible that physical cues differentially regulate the proliferation of myeloid leukemia subtypes through the autocrine secretion of TGF-β. In addition, cell-generated mechanical tension resulting from matrix stiffening may increase release of matrix-bound active TGF-β (31). In contrast to K-562, the effect of stiffness on growth of MOLM-14 and U-937 is biphasic, suggesting the presence of other autocrine factors secreted specifically in stiffer matrices that suppress proliferation (Fig. 2 A and B) . Delineating the interplay between specific growth factors and physical cues will thus be important to understand how matrix stiffness in the tumor microenvironment differentially regulates myeloid leukemias with distinct mutations.
Although a number of molecular targets are known to be involved in matrix stiffness sensing, most previous studies were performed with compounds at a single concentration. However, this approach does not reveal whether drug sensitivity against each target is influenced by matrix mechanics. This is an important consideration, because for drug targets whose inhibition depends on matrix stiffness a very high dose needs to be used to achieve similar efficacies in different physical environments, and this could increase the risk of off-target effects and toxicity. For instance, blebbistatin, an inhibitor against the myosin-II motor, at a high dose is known to eliminate differences in cellular functions and phenotypes caused by changes in matrix stiffness (5). However, higher concentrations of blebbistatin show off-target effects in some myosin-II mutant cells (32) . Indeed, our results suggest that matrix stiffness modulates the sensitivity of cells against blebbistatin (Fig. 3A) . Our 3D screen approach thus helps delineate how drug actions against different targets depend on mechanical cues for individual cancer subtypes, which could then further allow the identification of compounds that can potently target cells regardless of their physical environments.
It has been suggested that the tumor microenvironment induces the dormancy of leukemia cells, and hence they become more resistant to anticancer drugs due to slow proliferation (33) . However, increasing evidence suggests that the cytotoxic effects of chemotherapeutic agents are not likely dependent on proliferation in human tumors (34) . Indeed, adhesion of AML cells to matrix or stromal cells is known to decrease chemosensitivity, regardless of alterations in proliferation rates (35) . Consistent with this notion, no clear correlation was observed between cell proliferation and drug sensitivity in our screen. In addition, although K-562 growth is independent of RGD (Fig. 1B) it mediates chemosensitivity regulated by matrix mechanics (Fig. S4A) . Therefore, chemosensitivity may not always be a function of cell proliferation in pathophysiological contexts, providing evidence against the antiproliferative hypothesis.
We demonstrate the utility of implanting the same hydrogels used in an in vitro screen into xenograft models to bridge the gap between in vitro and in vivo preclinical studies. Although it is presently difficult to control matrix stiffness orthotopically in BM for systemic leukemia models, s.c. implantation models the extramedullary manifestation of leukemias, which often predicts rapid disease progression and poor prognosis in advanced-stage patients (36) . Even though in vivo tumor growth is a complex process that involves angiogenesis and matrix remodeling after implantation, the impact of stiffness on growth kinetics parameters of K-562 cells in vitro (Fig. S6B) are consistent with those in vivo (Fig. 5A ). This suggests that matrix stiffness is a dominant parameter that regulates tumor growth.
The s.c. xenograft model can also be used to study drug resistance against human leukemias, because chemotherapy adequate to induce marrow remission does not always control the extramedullary sites due to a high probability of relapse (25) . Indeed, the dose of Ara-C used in previous studies to control systemic leukemias (6.25 mg/kg) (37) is not sufficient to induce regression in s.c. sites (Fig. S6F) . Upon dose escalation, leukemia cells become more sensitive to standard chemotherapy in the stiff matrix (Fig. 5B) where cells grow slowly but steadily (Fig.  5A) , again providing evidence against the antiproliferative hypothesis. In contrast to previous studies with 2D plastic culture, Ara-C acts on leukemias originating from the stiff matrix by increasing the deceleration rate rather than decreasing the growth rate, suggesting involvement of additional mechanisms in its tumor effect in vivo. One possible explanation is that Ara-C increases apoptosis (Fig. S8A) , giving rise to augmented compensatory proliferation of surviving cells (Fig. S6 D, i) , as previously observed in chemical hepatocarcinogenesis (38) .
YAP is relatively low in hematopoietic cells compared with other cell types (Fig. S8B) (18) , and this could explain why leukemia cells are generally resistant to a YAP inhibitor alone (Fig. 3) . Although a functional significance of YAP up-regulation in in vivo implanted K-562 cells upon matrix stiffening (Fig. S8B) remains to be determined, it was previously shown that YAP overexpression (ii) Ara-C increases deceleration rate in stiff but not in soft matrix. (iii) Ara-C decreases tumor volume at week 6 in stiff but not in soft matrix. n = 6 mice, two experiments, *P < 0.01 from one-way ANOVA with Tukey's HSD test, stiff control vs. treated.
increases cisplatin-induced apoptosis of breast cancer cells in the presence of p73, which is activated by DNA damage (39) . The results thus suggest a possibility that up-regulation or increased nuclear localization of YAP upon matrix stiffening (29) may sensitize some leukemia cells against chemotherapeutic drugs that target DNA.
Overall, we present a combined biophysical screening and in vivo validation workflow that could be applied to a range of cancers to reveal their growth kinetics and pharmacodynamics profiles as a function of physical environments. The resistance of leukemia cells against standard chemotherapy with matrix softening underscores the utility of this quantitative approach for investigating physically induced cellular drug resistance and discovering molecular targets that can be potentially modulated across different mechanical environments.
Methods
Cell culture, mechanical characterization of hydrogels, in vivo tumor growth studies, mathematical modeling, and other standard techniques are described in SI Methods. All animal work was performed in compliance with NIH and the ethical committee from Harvard University.
For chemical screen in hydrogels, cells in culture were washed two times, followed by resuspension in the serum-free Fluorobrite DMEM media. Cells were then mixed with the alginate solution to make the final gel concentration of 1%. Eighty microliters of the cell-alginate mixture was then deposited into each well of a 96-well plate (U-Bottom; Corning) that contained different concentrations of 5× calcium sulfate (20 μL). Immediately after deposition, the content was rapidly mixed by swirling with pipette tips and pipetting up and down ∼10 times. The plate was then incubated at 37°C for 2 h to allow gels to form, and 100 μL of phenol red-free RPMI with 10% FBS was added on top of each gel; 1,000-10,000 cells were plated per well. Doseresponse curves at day 7 were obtained for 20 drugs titrated at five or more doses (1/3∼1/10 serial dilutions) ( Table S1 ). The proliferation of unlabeled cells was measured by alamarBlue (Invitrogen), and that of mCherry + cells was measured by reading fluorescence signals (emission 587 nm and excitation 620 nm). Hydrogel Preparation and Mechanical Characterizations. Sodium alginate with a low molecular weight (LF10/60) was purchased from FMC Biopolymer and prepared as described previously (40) . Briefly, alginate was dialyzed against deionized water for 3 d (molecular weight cutoff of 3,500 Da), filtered with activated charcoal, sterilefiltered, and lyophilized. It was then reconstituted in serum-free, phenol red-free DMEM at 4% (wt/vol) as a stock dilution. In some cases, an RGD peptide (GGGGRGDSP; Peptides International) was conjugated to alginate using carbodiimide chemistry at concentrations such that 5 or 20 RGD peptides were coupled to 1 alginate polymer on average. The coupling efficiency was previously characterized (40) . The gels were formed by mixing alginate with different concentrations of calcium sulfate. The mechanical properties of alginate hydrogels were characterized with an AR-G2 stress-controlled rheometer (TA Instruments) by directly depositing them onto the surface plate of the rheometer. A 20-mm plate was brought down before the alginate started to gel, and the mechanical properties were then measured over time, with the storage modulus recorded at 0.5% strain and at 1 Hz. The storage modulus at these settings was measured to range from 25 to 1,000 Pa, which corresponds to Young's modulus ranging from 75 to 3,000 Pa, using the equations E=2Gð1+υÞ and
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, where E = Young's modulus, v is Poisson's ratio of 0.5, G is the shear modulus, G′ is the shear storage modulus, and G′′ is the shear loss modulus.
Establishing Cell Lines That Express Exogenous Genes. To introduce mCherry and firefly luciferase in leukemia cells, lentiviral particles containing the vector with mCherry-IRES-firefly luciferase driven by the CMV promoter were purchased from the Vector Core at Massachusetts General Hospital. Cells were incubated with viral particles for 2 d. Single cells expressing mCherry were then sorted into 96-well plates via flow-activated cell sorting (FACS). Individual clones were expanded for 14 d. Clones were selected for further in vitro and in vivo analyses according to proliferation kinetics and intensity of fluorescence and luminescence signals. For MLL-AF9 transduction, retroviral particles were obtained by cotransfecting the vector containing MLL-AF9 or no gene ("empty") with the neomycin resistance gene and the packaging vector into Human Embryonic Kidney (HEK)-293 cells, followed by collection of supernatant at days 2-3 and ultracentrifugation through Amicon Ultra-15 (3-kDa cutoff ; Millipore) filters to concentrate particles. After introducing particles into leukemia cells, they were treated with G-418 (Invitrogen) to select for virally transduced cells. For BCR-ABL transduction, nerve growth factor receptor (NGFR) P210 (plasmid 27486) was a gift from Warren Pear, Addgene, Cambridge, MA, along with NGFR empty vector (plasmid 27489; Addgene) as previously published (41) . Retroviral particles were obtained and used for transduction in a fashion similar to MLL-AF9. After transduction, NGFR-positive cells were sorted by FACS and expanded. The sorting and expansion cycle was repeated two to three times to achieve >95% of NGFRpositive cells for drug studies.
Tumor Growth Studies in Localized Xenograft Extramedullary Leukemia Models. All animal experiments were performed in compliance with NIH and institutional guidelines approved by the ethical committee from Harvard University. K-562 cells (10 6 ) expressing mCherry and firefly luciferase were encapsulated in a 5-mm diameter × 1-mm height alginate gel disk (∼20 μL). A pair of gel discs with E = 100 or 3,000 Pa was s.c. implanted into each flank of 8-to 12-wk-old NOD/SCID/IL-2γ −/− mice. To monitor in vivo tumor growth over time, 3 mg D-luciferin was injected intraperitoneally into the 25-g mice followed by luminescence imaging with the IVIS Spectrum (PerkinElmer) within 30 min of injection. Average radiance (photons per second per centimeter squared per steradian) from each time point was measured from each implant for the first 3 wk. Beyond this time point, bioluminescence becomes saturated (Fig.  S6E) , and tumor volume was assessed using calipers by the modified ellipsoid formula: 1/2 × (length × width 2 ) (42).
Hierarchical Clustering Analysis. Before analysis, dose-response parameters, including IC 50 and AUC values, of each drug from different stiffnesses were normalized against their respective values on plastic followed by log transformation. m values were not normalized. The complete linkage method with Euclidean distance measure was implemented using R (heatmap.2 function; https://www.r-project.org/) to perform hierarchical clustering of the dose-response data.
Intracellular Flow Cytometry. Cells were retrieved from cross-linked hydrogels by digesting with alginate lyase (3.4 mg/mL) for 15 min at 37°C. Cell suspensions were then immediately fixed with 4% (wt/vol) paraformaldehyde for 10 min, followed by washing two times with PBS/0.1% BSA. Cells were then washed and resuspended in the staining media (PBS/0.1% saponin). Primary antibodies against total AKT and pAKT (Ser-473) were added to cells at 1:100 dilution along with Hoechst 33342 at 1:5,000 dilution. Cells were incubated at room temperature for 2 h. They were then washed with PBS and incubated with secondary antibodies (Alexa 647 anti-rabbit and Alexa 488 anti-mouse) for 30 min, followed by resuspension in PBS. Flow cytometry analysis was done using LSR II (BD).
Correlation Analysis. To observe relationships between Gompertz growth parameters and doses (normalized by IC 50 values on plastic) in different matrix stiffnesses, Spearman correlation analyses were performed using GraphPad Prism 6. In some cases where cells were treated with higher drug doses the data could not be fitted to the Gompertz kinetics because cells did not proliferate significantly over time, and therefore they were excluded from correlation analysis. A correlation is considered statistically significant if P < 0.05.
Curve Fitting. The pharmacodynamics data were fitted to the logistical sigmoidal function
where Y is the cell number at dose X, Max and Min are the top and bottom asymptotes of the response, respectively, IC 50 is the concentration at half-maximal effect (potency), and m is the Hill slope. Constraints are Min = 0 (i.e., absolute IC 50 ) and m > 0. Area under dose-response curve (AUC) values were calculated over five doses using the trapezoid rule. Nonlinear least-squares regression was performed in GraphPad Prism 6. More than 90% of all of the dose-response data followed the sigmoidal model with R 2 > 0.7 and were used for further analyses. Effects of matrix stiffening on AML cell number were fitted to the biphasic curve function
Where Y is the cell number at stiffness X (log scale), Init, Final, and Max are the cell numbers at the initial, final, and maximum plateau phases, respectively, EC 50 is the stiffness at half-maximal effect when cell number increases, IC 50 is the stiffness at halfmaximal effect when cell number decreases, and m1 and m2 are Hill slopes.
Cell Proliferation Kinetics Curve Fitting. The Gompertz function is defined as follows:
where N(t) is the cell number at time t, K1·G(t) is the growth rate at time t [i.e., K1·G(0) is the initial growth rate], and K2 is the deceleration rate. These differential equations can be solved analytically, resulting in the following equation:
This equation was used to fit the cell proliferation kinetics data at different doses and different stiffnesses. Nonlinear least-squares regression was performed in GraphPad Prism 6. More than 70% of all of the proliferation kinetics data followed this model with R 2 > 0.7 and were used for further analyses. Transforming N(t) to the natural log scale will lead to the firstorder growth kinetics equation:
Á .
The log scale data from the in vivo tumor growth analysis for the first 3 wk were fit to this equation. For each fit, a Y-intercept was extrapolated, and each value was subtracted from the Y-intercept to correct for the background signal. Bioluminescence signals become saturated at week 4 ( Fig. S6E) , and hence the data beyond this time point were not used for fitting. One way to compare luminescence signals between soft and stiff matrices is Y = lnðAXÞ lnðXÞ = lnðAÞ lnðXÞ
where A is the fold difference in luminescence between soft and stiff, Y is the ratio between soft and stiff at the natural log scale, and X is the raw luminescence signal of the stiff matrix. Therefore,
For example, at week 2 when X = 316.2 and Y = ∼1.8, A is ∼100 (Fig. S6C) .
Modeling an Autocrine Feedback Circuit of AML Cell Proliferation
Modulated by Matrix Stiffening. We constructed a simple set of differential equations to describe an autocrine feedback circuit ( Fig. 2 B, i) as follows:
where L is the number of leukemia cells at time t, c is the concentration of factors secreted from cells at time t, β(E) is the rate of proliferation at matrix stiffness E, δ(E) is the rate of factor secretion at E, α(c) is the cell death rate at c, and γ is the factor degradation rate. These equations were solved computationally using MATLAB (MathWorks) with the function ode45 and the following values: γ = 0.5, α(c) = c.
where βE 50 is the E at half-maximal proliferation rate, m β is the maximal proliferation rate, and k β is the Hill coefficient of the proliferation rate.
where δE 50 is the E at half-maximal factor secretion rate, m δ is the maximal secretion rate, and k δ is the Hill coefficient of the secretion rate.
To solve these equations analytically, at the steady state (ss), dL/dt = 0 and dc/dt = 0, and hence:
From Eq. S1: βðEÞ = αðcÞ = c ss .
From Eq. S2:
After substituting c ss with βðEÞ, δðEÞL ss = γβðEÞ L ss = γβðEÞ δðEÞ
[S5]
Plotting L ss vs. E of Eq. S5 with the initial L ss = 20, γ = 0.5, m β = 10, m δ = 1, k β = 2, k δ = 1 shows different biphasic curves with varied δE 50 and βE 50 as in Fig.  2A . Also, the equation suggests that the cell number will reach plateau with high E at
Analysis of an Alternative Model. Although the model in Fig. 2A considers when the proliferation rate is a function of matrix stiffness, and the death rate is a function of the secreted factors, it is possible that both proliferation and death rates directly depend on secreted factors as shown previously (21) .
where βc 50 is the c at half-maximal proliferation rate, m β is the maximal proliferation rate, and k β is the Hill coefficient of the proliferation rate.
where δE 50 is the E at half-maximal factor secretion rate, m δ is the maximal secretion rate, and k δ is the Hill coefficient of the secretion rate. At the steady state (ss), dL/dt = 0 and dc/dt = 0: From Eq. S6, given α(c) = c:
css Ákβ = c ss .
[S10]
This suggests that c ss is independent of L or E. As in Eq. S5, consider the case when m β = 10 and k β = 2. Rearranging Eq. S10 leads to a quadratic equation:
Solving Eq. S11 leads to
[S12]
From Eq. S7, given γ = 0.5:
[S13]
For a biphasic "concave-down" curve to exist there has to be a plateau at some value of E above zero. In other words,
However,
The only solution is E = 0 when k δ < −1. No solution exists when
. Hence, no biphasic relationship between cell number and matrix stiffness is observed at the steady state in this case.
Network Analysis of Signaling Pathways. A physical interaction network consisting of drug targets ("nodes") in this study was constructed using Cytoscape, open-source software for network analysis (43) . The physical interaction data were derived from multiple databases through the software, including BioGrid and MiMI. The results from previous tandem affinity purification and immunoprecipitation experiments with human cells were used for analysis. The results were filtered further based on previously reported confidence scores (>0.3 out of 1.0) for each interaction that were computed from the number of interactions and type of experiment, and the number of citations provided for each interaction. The total of 19 nodes and 41 interactions were used to construct the network. The interactions were then clustered on the basis of network topology or "interconnectedness" by using the clusterMaker2 plugin and the GLay Community Clustering algorithm, which identifies heavily connected subclusters via iterative removal of edges from the network. Three distinct clusters were identified and plotted in the interaction map. Arrows were assigned based on established knowledge on AKT and MAPK pathways. Interactions within the same cluster were colored black, and those in different clusters were colored gray. 
